Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: Results of a phase II study

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Rozzi, Antonio ^a   Santini, Daniele ^b   Salerno, Margherita ^c   Bordin, Francesca ^a   Mancuso, Andrea ^d   Minniti, Giuseppe ^e,f   Nardoni, Chiara ^a   Corona, Michela ^a   Falbo, Pina Tiziana ^a   Recine, Federica ^d   Lanzetta, Gaetano ^a,f  

^a Istituto Neurotraumatologico Italiano (INI)   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c Palliative Care Center SAntonio da Padova   (Italy)

^d SCamillo Forlanini General Hospital   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f IRCCS NEUROMED   (Italy)

Author keywords

Pegylated liposomal doxorubicin; Third line chemotherapy; Transitional cell carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MALE; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; SALVAGE THERAPY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84872019367     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0407-5     Document Type: Article

References (9)

1. Sa Hussain. James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol. 2003;4:489-97.
2. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454-61.
3. Rozzi A, Salerno M, Bordin F, et al. Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study. Med Oncol. 2011;28:S426-32.
4. Han KS, Joung JY, Kim TS et al. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer. 2008 Jan 15;98(1):86-90. Epub 2007 Dec 18.
5. O'Brien MER, Wigler N, Inbar M, et al. CAELYX breast cancer study group: reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCL (Caelyx™/Doxil™) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440-9.
6. 2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology. 2006;70:141-6.
7. Winquist E, Ernst DS, Jonker D, et al. Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract. Eur J Cancer. 2003;39(13):1866-71.
8. Soga N, Kise H, Arima K, et al. Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer. Int J Clin Oncol. 2010;15(4):376-81.
9. Vaughn DJ, Hwang W, Munier C et al. Prognostic risk group classification for patients with platinum-refractory metastatic urothelial cancer treated with second-line chemotherapy. J Clin Oncol. 2009; 27:15 s (Suppl; abstr 5078).